KCAS-blog-thumb_2022_GLP-CGT Blogs
Read article Is GLP Bioanalysis needed to support your Cell and Gene Therapy GLP Tox Studies?

Cell and Gene Therapies (CGTs) has an estimated market size value in 2022 of USD 8.22 billion and a revenue forecast in 2030 of USD 24.5 billion. This is a CAGR (compound annual growth rate) of 14.6% from 2022 to 2030. Needless to say, the…

blue_pattern Blogs
Read article Dose Formulation Analysis Services from KCAS

Dose Formulation Analysis is an essential step in regulated nonclinical studies. Robust analytical methods, rapid turnaround, and efficient communication helps deliver your GLP studies’ dose formulation analysis results on time…

KCAS-blog-thumb_2022_immunophenotyping-1 Blogs
Read article Flow Cytometry Services: Immunophenotyping

Due to its ability to analyze multiple parameters across different cell types within a sample, flow cytometry provides rich and clinically valuable data sets from even small volumes of blood. However, flow cytometry is a challenging platform to master, and requires significant investment in equipment and technical training.

KCAS-blog-thumb_2022_CSK-World-Class-Service Blogs
Read article KCAS Provides World-Class Clinical Sample Kitting Services, with Experience in Shipping Around the Globe

KCAS established our Clinical Sample Kitting team in the early 1990s in response to shortcomings we observed in the collection techniques in trials where we were providing bioanalytical support. As the group has evolved, our aim has been to provide the flexible, custom service that…

KCAS-blog-thumb_2022_QA-Book-w-Shane Blogs
Read article KCAS Invited by Society of Quality Assurance to Co-Author Guidance Book on Electronic Data Integrity & Data Quality

After an open call that went out earlier this year, Shane De Büchel, Sr Manager of Quality Assurance (Compliance & Systems) at KCAS, has been selected as one of roughly 50 members of the Society of Quality Assurance to collaborate in authoring an upcoming data integrity book (the…

KCAS-blog-thumb_2022_Molecular-CGT Blogs
Read article Molecular Cell & Gene Therapy Solutions from KCAS

With the extensive advances in technologies like CRISPR and CAR-T, cell and gene therapy has grown to become a viable way for treating Cancer as well as other diseases. Our team has over 100+ years of collective expertise in molecular services using qPCR and ddPCR for support of…

KCAS-blog-thumb_2022_Lipidomics-Discussion News
Read article KCAS Invited to Lead Discussion on “Clinical and Translational Lipidomics” at Upcoming Gordon Research Conference

Dawn Dufield, PhD, Senior Director of Biopharmaceutical LC-MS/MS Services at KCAS, has been invited to lead a workshop discussion session on Lipidomics at an upcoming Gordon Research Conference from August 7-12 in Newry, ME. The event will be a week long conference highlighting recent developments in standardization, omics integration,…

KCAS-blog-thumb_2022_Webinar-CGT-June-2022-1 Webinars
View webinar Upcoming KCAS Webinar (June 24th): “The Age of Cell and Gene Therapies is Upon Us – So What Does That Mean for Bioanalysis?”

Being produced by Xtalks on Friday, June 24, 2022 | 12pm EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central) 60 min Webinar Description: Cell and gene therapies (CGTs) are types of treatment that use cellular or genetic material with the goal of treating a disease or a…

KCAS-blog-thumb_2022_Paper-w-Gilead-Cyclodextrin-1 Blogs
Read article KCAS Invited by Gilead to Develop Challenging Assay to Quantitate Drug Delivery Vehicle

Dr. Sohrab Habibi Goudarzi – Senior Director of Pharma Discovery and R&D Services, Bryan Parmentier – Senior Principal Scientist of Pharma Method Development, and Yu-Hui (Ann) Fu -Principal Scientist of Pharma Regulatory, along with other scientists at KCAS Bioanalytical & Biomarker Services, coauthored with scientists at Gilead Sciences, Inc. in…

KCAS-blog-thumb_2022_Webinar-Hybrid-Gold-Standard-1 Webinars
View webinar KCAS Webinar: “Is Hybrid LC-MS/MS becoming the new Gold Standard?”

Originally produced by Xtalks on Friday, April 22, 2022 | 12pm EDT (NA) / 5pm BST (UK) / 6pm CEST (EU-Central)  60 min Webinar Description: Due to the relative maturity of the technology, most people’s instinct when thinking about bioanalysis of large molecules is towards ligand binding assays.

PATTERN_AMBER_1320x780_2 Blogs
Read article The Age of Cell & Gene Therapies is Upon Us. So What Does That Mean?

Cell and Gene Therapies (CGTs) are types of treatment that uses cellular or genetic material with the goal of treating a disease or a disordered. Often it can be a combination of cell and gene therapies, which is the case for Chimeric antigen receptor T cells (CAR T-Cells).  As of…

KCAS-blog-thumb_2022_Hybrid-New-Gold-Standard-1 Blogs
Read article Is Hybrid LC-MS/MS becoming the new Gold Standard?

Due to the relative maturity of the technology, most people’s instinct when thinking about bioanalysis of large molecules is towards ligand binding assays. However, we urge people to be open to a more flexible approach. Using hybrid LC-MS/MS can be an equally useful tool for quantitation of biological therapeutics and…